Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + 1-phosphatidyl-1D-myo-inositol 3-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate
-
poor substrate compared to 1-phosphatidyl-1D-myo-inositol 5-phosphate
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + dipalmitoyl-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + dipalmitoyl-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
663208, 721493, 721525, 723602, 737401, 737789, 738171, 758575, 758945, 759023, 759615 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
phosphorylation at the D-4 position
-
?
additional information
?
-
-
although PIP4K II generates PI-4,5-P2, a substrate for PI3K, expression of this enzyme reduces rather than increases phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) levels in cells stimulated with insulin or cells expressing activated PI3K, this reduction in PI-3,4,5-P3 levels results in decreased activation of the downstream protein kinase Akt/PKB, expression of IpgD, a bacterial phosphatase that converts PI-4,5-P2 to PI-5-P, results in Akt activation, and this effect is partially reversed by PIP4K IIbeta, PIP4K IIbeta expression does not impair insulin-dependent association of PI3K with insulin receptor substrate 1 IRS1 but abbreviates Akt activation, indicating that PIP4K II regulates PI-3,4,5-P3 degradation rather than synthesis
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2,4-diamino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
3-(trifluoromethyl)phenyl 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylate
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-(3-phenoxyphenyl)pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-methyl-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(benzylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(methylsulfanyl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(piperidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-hydroxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-methoxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[(2,2-dimethylpropyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[(tert-butylcarbamoyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[[(1-methyl-1H-pyrazol-5-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-N-(1,3-benzothiazol-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-(1-benzothiophen-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-[3-(trifluoromethyl)phenyl]-2-(3,4,4-trimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
(2E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
-
-
(2E)-2-(3,4-dihydroxybenzoyl)-3-(4-hydroxy-3-iodo-5-methoxyphenyl)prop-2-enenitrile
-
-
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
-
(2Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)prop-2-enenitrile
-
-
(3E)-5-amino-3-[(2Z)-1-cyano-2-(3H-indol-3-ylidene)ethylidene]-2,3-dihydro-1H-pyrazole-4-carbonitrile
-
-
(3Z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
-
-
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
-
-
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
-
-
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
-
-
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
-
-
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
-
-
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
-
-
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
i.e. CVM-05-002, potent and selective inhibitor for isoform PI5P4Kalpha
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
-
5-[3-(methylsulfonyl)phenyl]-4-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]thieno[2,3-d]pyrimidine
-
-
AG-538
-
at a concentration of 0.02 mM, AG-538 induces an almost complete inhibition of isoform PI5P4Kalpha and inhibits isoforms PI5P4Ks beta and gamma by 90% and 85%, respectively
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
-
-
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
-
-
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
-
-
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
piperine
-
complete inhibition at 0.1 mM
tyrphostin
-
ATP-competitive inhibitors, i.e. tyrosine phosphorylation inhibitors, of isozyme PI5P4Kalpha
additional information
-
high-throughput inhibitor screening method, counterscreen assay and ATP competition assay, overview
-
NIH-12848
-
-
NIH-12848
-
very specific inhibitor
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Alzheimer Disease
Cl(-)-ATPase in rat brain and kidney.
Amyotrophic Lateral Sclerosis
VAMP associated proteins are required for autophagic and lysosomal degradation by promoting a PtdIns4P-mediated endosomal pathway.
Astrocytoma
Inhibition of beta(2)-adrenergic and muscarinic cholinergic receptor endocytosis after depletion of phosphatidylinositol bisphosphate.
Autoimmune Diseases
PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity.
Bacterial Infections
Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks.
Breast Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Breast Neoplasms
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
Breast Neoplasms
Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.
Carcinogenesis
PIP4K2B: Coupling GTP Sensing to PtdIns5P Levels to Regulate Tumorigenesis.
Carcinogenesis
Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.
Carcinoma
Phosphatidylinositol 4-kinase assay in ovarian carcinoma cells.
Carcinoma
Signalling and non-caveolar rafts.
Carcinoma
The tetraspanin D6.1A and its molecular partners on rat carcinoma cells.
Carcinoma, Hepatocellular
Overexpression of phosphatidylinositol 4-kinase type III? is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.
Colonic Neoplasms
Identification of Metabolic-Associated Genes for the Prediction of Colon and Rectal Adenocarcinoma.
Cystic Fibrosis
Distinct and specific functions of cGMP-dependent protein kinases.
Deafness
Phosphatidylinositol 4-kinase ? mutations cause nonsyndromic sensorineural deafness and inner ear malformation.
Dehydration
Importance of inositols and their derivatives in cowpea under root dehydration: An omics perspective.
Diabetes Mellitus, Type 2
Increased insulin sensitivity and reduced adiposity in phosphatidylinositol 5-phosphate 4-kinase beta-/- mice.
Encephalitis
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Fibrosarcoma
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Gallbladder Neoplasms
C24 -Ceramide Drives Gallbladder Cancer Progression through Directly Targeting PIP4K2C to Facilitate mTOR Signaling Activation.
Glioblastoma
PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma.
Hematologic Neoplasms
Differential profile of PIP4K2A expression in hematological malignancies.
Hematologic Neoplasms
Identification and characterization of human ARHGAP23 gene in silico.
Hematologic Neoplasms
PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia.
Hepatitis C
Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.
Hepatitis C
Fluorescent Inhibitors as Tools To Characterize Enzymes: Case Study of the Lipid Kinase Phosphatidylinositol 4-Kinase III? (PI4KB).
Hepatitis C
Hepatitis C virus NS5A protein cooperates with phosphatidylinositol 4-kinase III? to induce mitochondrial fragmentation.
Hepatitis C
Hepatitis C Virus NS5A Protein Interacts with Phosphatidylinositol 4-Kinase Type III{alpha} and Regulates Viral Propagation.
Hepatitis C
Hepatitis C Virus Stimulates the Phosphatidylinositol 4-Kinase III Alpha-Dependent Phosphatidylinositol 4-Phosphate Production That Is Essential for Its Replication.
Hepatitis C
High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay.
Hepatitis C
Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.
Hepatitis C
Mutations in Encephalomyocarditis Virus 3A Protein Uncouple the Dependency of Genome Replication on Host Factors Phosphatidylinositol 4-Kinase III? and Oxysterol-Binding Protein.
Hepatitis C
Novel phosphatidylinositol 4-kinases III beta (PI4KIII?) inhibitors discovered by virtual screening using free energy models.
Hepatitis C
Overexpression of phosphatidylinositol 4-kinase type III? is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.
Hepatitis C
Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels.
Hepatitis C
The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement.
Hepatitis C
Tyrphostin AG1478 inhibits encephalomyocarditis virus and hepatitis C virus by targeting phosphatidylinositol 4-kinase III?.
Herpes Simplex
Deoxythymidine kinase induced in HeLa TK- cells by herpes simplex virus type I and type II. II. Purification and characterization.
Immune System Diseases
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Infections
A phase 1, placebo controlled, randomised, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics and antimalarial activity of the Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048.
Infections
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Infections
Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening.
Insulin Resistance
Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta.
Insulin Resistance
Increased insulin sensitivity and reduced adiposity in phosphatidylinositol 5-phosphate 4-kinase beta-/- mice.
Insulin Resistance
MANF regulates hypothalamic control of food intake and body weight.
Leukemia
Differential profile of PIP4K2A expression in hematological malignancies.
Leukemia
FcepsilonRI cross-linking activates a type II phosphatidylinositol 4-kinase in RBL 2H3 cells.
Leukemia
Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.
Leukemia, Myeloid, Acute
A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival.
Leukemia, Myeloid, Acute
Differential profile of PIP4K2A expression in hematological malignancies.
Leukemia, Myeloid, Acute
Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase.
Leukemia, Myeloid, Acute
PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia.
Lymphatic Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Malaria
Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities.
Malaria
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.
Myelodysplastic Syndromes
Differential profile of PIP4K2A expression in hematological malignancies.
Neoplasm Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasm Metastasis
Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.
Neoplasm Metastasis
Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.
Neoplasms
Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer.
Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasms
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Neoplasms
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Neoplasms
Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KII? as anti-tumor strategy.
Neoplasms
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.
Neoplasms
Identification and characterization of human ARHGAP23 gene in silico.
Neoplasms
Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression.
Neoplasms
Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.
Neoplasms
Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks.
Neoplasms
Novel phosphatidylinositol 4-kinases III beta (PI4KIII?) inhibitors discovered by virtual screening using free energy models.
Neoplasms
Pharmacological inhibition of PI5P4K?/? disrupts cell energy metabolism and selectively kills p53-null tumor cells.
Neoplasms
Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.
Neoplasms
PIP4K and the role of nuclear phosphoinositides in tumour suppression.
Neoplasms
PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia.
Neoplasms
PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma.
Neoplasms
PIP4K2B: Coupling GTP Sensing to PtdIns5P Levels to Regulate Tumorigenesis.
Neoplasms
PIP4Kbeta interacts with and modulates nuclear localization of the high-activity PtdIns5P-4-kinase isoform PIP4Kalpha.
Neoplasms
PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity.
Neoplasms
PtdIns5P is an oxidative stress-induced second messenger that regulates PKB activation.
Neoplasms
Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.
Neoplasms
Silencing of type II phosphatidylinositol 4-kinase ? stabilizes prostate apoptosis response-4 and induces apoptosis in cancer cells.
Neoplasms
Targeting Phosphatidylinositol 4-Kinase III? for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent.
Neoplasms
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Neoplasms
The functions of Atg8-family proteins in autophagy and cancer: linked or unrelated?
Neoplasms
The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature.
Neoplasms
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design.
Neoplasms
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.
Neuralgia
Netrin-1 contributes to peripheral nerve injury induced neuropathic pain via regulating phosphatidylinositol 4-kinase IIa in the spinal cord dorsal horn in mice.
Neuroblastoma
Attenuation of focal adhesion kinase signaling following depletion of agonist-sensitive pools of phosphatidylinositol 4,5-bisphosphate.
Neuroinflammatory Diseases
Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage.
Obesity
Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta.
Pancreatic Neoplasms
Correction to: Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression.
Pancreatic Neoplasms
Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression.
Paraplegia
Mouse models for hereditary spastic paraplegia uncover a role of PI4K2A in autophagic lysosome reformation.
Peripheral Nerve Injuries
Netrin-1 contributes to peripheral nerve injury induced neuropathic pain via regulating phosphatidylinositol 4-kinase IIa in the spinal cord dorsal horn in mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ARID5B, CEBPE and PIP4K2A Germline Genetic Polymorphisms and Risk of Childhood Acute Lymphoblastic Leukemia in Mexican Patients: A MIGICCL Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association Between PIP4K2A Polymorphisms and Acute Lymphoblastic Leukemia Susceptibility.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BMI1 enhancer polymorphism underlies chromosome 10p12.31 association with childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential profile of PIP4K2A expression in hematological malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.
Rectal Neoplasms
Identification of Metabolic-Associated Genes for the Prediction of Colon and Rectal Adenocarcinoma.
Sarcoma, Avian
Differential expression of type I and type II cyclic AMP-dependent protein kinases during cell cycle and cyclic AMP-induced growth arrest.
Severe Acute Respiratory Syndrome
Fluorescent Inhibitors as Tools To Characterize Enzymes: Case Study of the Lipid Kinase Phosphatidylinositol 4-Kinase III? (PI4KB).
Severe Acute Respiratory Syndrome
Phosphatidylinositol 4-Kinase III? Is Required for Severe Acute Respiratory Syndrome Coronavirus Spike-mediated Cell Entry.
Spastic Paraplegia, Hereditary
Mouse models for hereditary spastic paraplegia uncover a role of PI4K2A in autophagic lysosome reformation.
Spastic Paraplegia, Hereditary
Screening for mutations in the phosphatidylinositol 4-kinase 2-alpha gene in autosomal recessive hereditary spastic paraplegia.
Stomach Neoplasms
Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.
Tuberculosis
Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery.
Virus Diseases
Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks.
Virus Diseases
Novel phosphatidylinositol 4-kinases III beta (PI4KIII?) inhibitors discovered by virtual screening using free energy models.
Virus Diseases
The Molecular Basis of Aichi Virus 3A Protein Activation of Phosphatidylinositol 4 Kinase III?, PI4KB, through ACBD3.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0026 - 0.0101
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
0.0019
(2Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)prop-2-enenitrile
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0021 - 0.0089
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.0038
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.00199 - 0.0356
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.002 - 0.0318
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
0.0035 - 0.0158
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.0013 - 0.0062
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
0.00134 - 0.0099
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
0.0065 - 0.0205
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.0053 - 0.0336
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
0.0052 - 0.0298
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
0.0174 - 0.0304
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
0.0193 - 0.0245
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
0.0013 - 0.0063
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
0.0026
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0101
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0021
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0089
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.00199
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0021
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0109
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0356
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.002
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0318
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0035
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0158
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0013
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0062
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.00134
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0099
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0065
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0205
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0053
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0336
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0052
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0298
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0174
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0304
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0193
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0245
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0013
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0063
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.03
2,4-diamino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
3-(trifluoromethyl)phenyl 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylate
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0054
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-(3-phenoxyphenyl)pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-methyl-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0081
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.013
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.025
4-amino-2-(benzylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-2-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-(methylsulfanyl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-(piperidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-hydroxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-methoxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.008
4-amino-2-[(2,2-dimethylpropyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-2-[(tert-butylcarbamoyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0041
4-amino-2-[[(1-methyl-1H-pyrazol-5-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.025
4-amino-N-(1,3-benzothiazol-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.013
4-amino-N-(1-benzothiophen-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-N-[3-(trifluoromethyl)phenyl]-2-(3,4,4-trimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0038
SAR088
Homo sapiens
at pH 7.4 and 26°C
0.014
(2E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.002
(2E)-2-(3,4-dihydroxybenzoyl)-3-(4-hydroxy-3-iodo-5-methoxyphenyl)prop-2-enenitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.013
(3E)-5-amino-3-[(2Z)-1-cyano-2-(3H-indol-3-ylidene)ethylidene]-2,3-dihydro-1H-pyrazole-4-carbonitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.005
(3Z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.0061 - 0.027
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.0018 - 0.0086
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
0.035 - 0.05
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
0.011 - 0.05
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
0.026 - 0.05
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
0.0039 - 0.05
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
0.0014 - 0.0043
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
0.0088 - 0.05
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
0.028 - 0.05
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
0.011 - 0.05
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
0.00066 - 0.0027
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.021 - 0.05
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.00013 - 0.0019
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.011 - 0.05
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
0.00027 - 0.0017
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.004 - 0.025
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.014 - 0.045
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
0.009 - 0.025
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
0.0053 - 0.036
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
0.002 - 0.0094
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0089 - 0.015
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0037 - 0.043
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
0.0021 - 0.022
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0032 - 0.029
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
0.00095 - 0.0059
THZ-P1-2
0.001
tyrphostin
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.045
tyrphostin 23
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.02
tyrphostin 47
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.1
tyrphostin AG 1478
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.089
tyrphostin AG 490
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.089
tyrphostin AG 494
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.032
tyrphostin AG 537
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.055
tyrphostin AG 555
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.05
tyrphostin AG 698
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.018
tyrphostin AG 808
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.0061
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.027
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0018
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0086
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.035
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.011
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.026
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0039
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0014
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0043
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0088
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.028
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.05
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.011
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00066
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0027
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.021
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00013
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0019
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.011
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00027
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0017
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.004
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.025
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.014
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.045
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.009
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.025
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0053
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.036
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.002
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0094
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0089
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.015
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0037
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.043
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0021
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.022
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0032
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.029
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00095
THZ-P1-2
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0059
THZ-P1-2
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.5 and °C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Rameh, L.E.; Tolias, K.F.; Duckworth, B.C.; Cantley, L.C.
A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate
Nature
390
192-196
1997
Homo sapiens
brenda
Carricaburu, V.; Lamia, K.A.; Lo, E.; Favereaux, L.; Payrastre, B.; Cantley, L.C.; Rameh, L.E.
The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation
Proc. Natl. Acad. Sci. USA
100
9867-9872
2003
Homo sapiens
brenda
Clarke, J.H.; Emson, P.C.; Irvine, R.F.
Localization of Phosphatidylinositol phosphate Kinase II gamma in kidney to a membrane trafficking compartment within specialized cells of the nephron
Am. J. Physiol. Renal Physiol.
295
F1422-1430
2008
Homo sapiens (Q8TBX8), Mus musculus (Q91XU3)
brenda
Richardson, J.P.; Wang, M.; Clarke, J.H.; Patel, K.J.; Irvine, R.F.
Genomic tagging of endogenous type IIbeta phosphatidylinositol 5-phosphate 4-kinase in DT40 cells reveals a nuclear localization
Cell. Signal.
19
1309-1314
2007
Gallus gallus, Homo sapiens (P78356)
brenda
Kouchi, Z.; Fujiwara, Y.; Yamaguchi, H.; Nakamura, Y.; Fukami, K.
Phosphatidylinositol 5-phosphate 4-kinase type II beta is required for vitamin D receptor-dependent E-cadherin expression in SW480 cells
Biochem. Biophys. Res. Commun.
408
523-529
2011
Homo sapiens
brenda
Bultsma, Y.; Keune, W.J.; Divecha, N.
PIP4Kbeta interacts with and modulates nuclear localization of the high-activity PtdIns5P-4-kinase isoform PIP4Kalpha
Biochem. J.
430
223-235
2010
Homo sapiens, Rattus norvegicus
brenda
Davis, M.I.; Sasaki, A.T.; Shen, M.; Emerling, B.M.; Thorne, N.; Michael, S.; Pragani, R.; Boxer, M.; Sumita, K.; Takeuchi, K.; Auld, D.S.; Li, Z.; Cantley, L.C.; Simeonov, A.
A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation
PLoS ONE
8
e54127
2013
Homo sapiens
brenda
Bulley, S.J.; Clarke, J.H.; Droubi, A.; Giudici, M.L.; Irvine, R.F.
Exploring phosphatidylinositol 5-phosphate 4-kinase function
Adv. Biol. Regul.
57
193-202
2015
Homo sapiens
brenda
Voss, M.D.; Czechtizky, W.; Li, Z.; Rudolph, C.; Petry, S.; Brummerhop, H.; Langer, T.; Schiffer, A.; Schaefer, H.L.
Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta
Biochem. Biophys. Res. Commun.
449
327-331
2014
Homo sapiens (P78356)
brenda
Clarke, J.H.; Irvine, R.F.
Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization
Biochem. J.
454
49-57
2013
Homo sapiens (P48426), Homo sapiens (P78356), Homo sapiens (Q8TBX8), Homo sapiens
brenda
Sinha, R.K.; Bojjireddy, N.; Kulkarni, D.; Ratheesh, A.; Chiplunkar, S.V.; Gude, R.; Subrahmanyam, G.
Type II phosphatidylinositol 4-kinase beta is an integral signaling component of early T cell activation mechanisms
Biochimie
95
1560-1566
2013
Homo sapiens
brenda
Boura, E.; Nencka, R.
Phosphatidylinositol 4-kinases: Function, structure, and inhibition
Exp. Cell Res.
337
136-145
2015
Homo sapiens
brenda
Bojjireddy, N.; Sinha, R.K.; Subrahmanyam, G.
Type II phosphatidylinositol 4-kinases interact with FcepsilonRIgamma subunit in RBL-2H3 cells
Mol. Cell. Biochem.
390
197-203
2014
Homo sapiens
brenda
Manz, T.D.; Sivakumaren, S.C.; Yasgar, A.; Hall, M.D.; Davis, M.I.; Seo, H.S.; Card, J.D.; Ficarro, S.B.; Shim, H.; Marto, J.A.; Dhe-Paganon, S.; Sasaki, A.T.; Boxer, M.B.; Simeonov, A.; Cantley, L.C.; Shen, M.; Zhang, T.; Ferguson, F.M.; Gray, N.S.
Structure-activity relationship study of covalent pan-phosphatidylinositol 5-phosphate 4-kinase inhibitors
ACS Med. Chem. Lett.
11
346-352
2020
Homo sapiens
brenda
Giudici, M.; Clarke, J.; Irvine, R.
Phosphatidylinositol 5-phosphate 4-kinase gamma (PI5P4Kgamma), a lipid signalling enigma
Adv. Biol. Regul.
61
47-50
2016
Homo sapiens
brenda
Mathre, S.; Reddy, K.B.; Ramya, V.; Krishnan, H.; Ghosh, A.; Raghu, P.
Functional analysis of the biochemical activity of mammalian phosphatidylinositol 5 phosphate 4-kinase enzymes
Biosci. Rep.
39
BSR20182210
2019
Homo sapiens
brenda
Lin, T.C.; Kuo, H.H.; Wu, Y.C.; Pan, T.S.; Yih, L.H.
Phosphatidylinositol-5-phosphate 4-kinase gamma accumulates at the spindle pole and prevents microtubule depolymerization
Cell Div.
14
9-9
2019
Homo sapiens
brenda
Manz, T.D.; Sivakumaren, S.C.; Ferguson, F.M.; Zhang, T.; Yasgar, A.; Seo, H.S.; Ficarro, S.B.; Card, J.D.; Shim, H.; Miduturu, C.V.; Simeonov, A.; Shen, M.; Marto, J.A.; Dhe-Paganon, S.; Hall, M.D.; Cantley, L.C.; Gray, N.S.
Discovery and structure-activity relationship study of (Z)-5-methylenethiazolidin-4-one derivatives as potent and selective pan-phosphatidylinositol 5-phosphate 4-kinase inhibitors
J. Med. Chem.
63
4880-4895
2020
Homo sapiens
brenda
Davis, M.; Sasaki, A.; Simeonov, A.
Method for assaying the lipid kinase phosphatidylinositol-5-phosphate 4-kinase alpha in quantitative high-throughput screening (qHTS) bioluminescent format
Methods Mol. Biol.
1376
1-9
2016
Homo sapiens (P48426)
brenda